Tags : Lymphoplasmacytic Lymphoma

ONO Reports Submission of MAA to MHLW for Tirabrutinib Hydrochloride

Shots: ONO has submitted manufacturing and marketing approval application to MHLW for the treatment of WM an LPL in Japan The application is based on P-II ONO-4059-05 study assessing Tirabrutinib in 27 patients with untreated recurrent or refractory WM and LPL. Additionally, ONO has applied for the manufacturing and marketing approval of Tirabrutinib to treat […]Read More